Letters to the Editor Annals of Surgery Volume 267, Number 3, March 2018 8. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant log-rank test). Survival of patients in margin University Hospital Carl Gustav Carus chemotherapy with gemcitabine and long-term group III was lower than that of patients in TU Dresden, Germany. outcomes among patients with resected pancre- margin group I (13 months, P < 0.001; log- Nuh.Rahbari@uniklinikum-dresden.de atic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. rank test) and margin group II (P ¼ 0.08; log- 9. O?Reilly EM, Perelshteyn A, Jarnagin WR, et al. rank test). Collectively, these data confirm the A single-arm, nonrandomized phase II trial of results of our initial report. neoadjuvant gemcitabine and oxaliplatin in REFERENCES The topic of margin clearance and out- patients with resectable pancreas adenocarci- come has been controversial owing to the lack 1. Nitschke P, Volk A, Welsch T, et al. Impact of noma. Ann Surg. 2014;260:142–148. intraoperative re-resection to achieve R0 status on of uniform guidelines for the processing of 10. Ferrone CR, Marchegiani G, Hong TS, et al. survival in patients with pancreatic cancer: a Radiological and surgical implications of neo- surgical specimens, reporting of pathological single-center experience
Annals of Surgery – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud